What You Should Know:
– Mika Health, a leading developer of digital therapeutics for cancer patients, announced a collaborative initiative called “UNITE” alongside pharmaceutical giants AstraZeneca and Daiichi Sankyo.
– The strategic initiative signifies a commitment…
Continue Reading
Oncology-focused digital therapeutics company Mika Health announced a partnership with pharma companies AstraZeneca and Daiichi Sankyo for an initiative dubbed “UNITE” to provide digital therapeutics to women undergoing breast cancer treatments. Mika Health’s app gives…
Continue Reading
What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic investment bolsters…
Continue Reading
A research collaboration between Brainomix and AstraZeneca has shown that Brainomix’s AI-powered e-Lung software can more accurately identify lung fibrosis patients most at risk of decline.Brainomix published a study in the peer-reviewed journal ‘American…
Continue Reading
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to…
Continue Reading
What You Should Know:
– AstraZeneca has announced the acquisition of Icosavax, a biopharmaceutical company developing a promising vaccine targeting both RSV and hMPV, for a total of up to $1.1 billion.
– This acquisition strengthens…
Continue Reading
Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help…
Continue Reading
What You Should Know:
– Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
– This…
Continue Reading
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
UK Biobank has today unveiled incredible new data from whole genome sequencing of its half a million participants, a step that is set to drive the discovery of new diagnostics, treatments and cures. The data, uniquely,…
Continue Reading
